Literature DB >> 18479591

[Correlation of epidermal growth factor receptor activation to metastasis-free survival of nasopharyngeal carcinoma patients].

Tai-Ze Yuan1, Xiao-Xia Li, Yun Cao, Chao-Nan Qian, Mu-Sheng Zeng, Xiang Guo.   

Abstract

BACKGROUND &
OBJECTIVE: Epidermal growth factor receptor (EGFR) is overexpressed in many tumors, and is correlated to poor prognosis. However, the prognostic value of EGFR expression in nasopharyngeal carcinoma (NPC) is controversial. This study was to investigate the expression of EGFR and its phosphorylated form (pEGFR) in NPC, and explore their correlations to the prognosis.
METHODS: NPC samples were obtained from 110 NPC patients treated at Cancer Center of Sun Yat-sen University from Jan. 1999 to Dec. 1999. The expression of EGFR and pEGFR in 110 specimens of NPC and 20 specimens of normal nasopharyngeal tissues were detected by immunohistochemistry. The correlations of EGFR and pEGFR expression to clinical characteristics and prognosis of NPC were analyzed by univariate and multivariate analyses.
RESULTS: The positive rates of EGFR and pEGFR were significantly higher in NPC than in normal tissues (100% vs. 10.0%, 60.0% vs. 15.0%, both P<0.001). High expression rate of EGFR was significantly higher in stage T3-4 tumors than in stage T1-2 tumors (63.6% vs. 43.2%, P=0.034), but it had no relationship with other clinical parameters. The 5-year metastasis-free survival rate was significantly lower in the patients with high pEGFR expression than in those with low pEGFR expression (72.2% vs. 91.0%, P=0.012). However, multivariate analysis revealed that pEGFR expression was not an independent prognostic factor for metastasis-free survival of NPC patients.
CONCLUSION: Phosphorylation of EGFR is related with metastasis-free survival of NPC patients, suggesting an important role of activation of EGFR in the dissemination of NPC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479591

Source DB:  PubMed          Journal:  Ai Zheng


  5 in total

1.  Quantitative study of cytotoxic T-lymphocyte immunotherapy for nasopharyngeal carcinoma.

Authors:  Wang Shengjun; Guo Yunbo; Song Liyan; Li Jinming; Deng Qinkai
Journal:  Theor Biol Med Model       Date:  2012-03-07       Impact factor: 2.432

2.  Adding Concurrent Chemotherapy Significantly Improves the Survival of Stage II-IVb Nasopharyngeal Carcinoma Patients Treated With Concurrent Anti-EGFR Agents.

Authors:  Zi-Kun Yu; Xu-Yin Chen; Si-Han Liu; You-Ping Liu; Rui You; Pei-Yu Huang
Journal:  Front Oncol       Date:  2021-12-17       Impact factor: 6.244

3.  Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis.

Authors:  Xishan Chen; Renba Liang; Lin Lai; Kaihua Chen; Xiaodong Zhu
Journal:  Front Oncol       Date:  2021-08-19       Impact factor: 6.244

4.  Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma.

Authors:  Huan-Huan Zhang; Tai-Ze Yuan; Jian Li; Yin Liang; Lai-Ji Huang; Jia-Cai Ye; Rong-Hui Zheng; Guo-Feng Xie; Xiu-Ping Zhang
Journal:  Exp Ther Med       Date:  2013-08-02       Impact factor: 2.447

5.  Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis.

Authors:  Xiaohua Hong; Guangyao Wang; Guanglan Xu; Wei Shi; Tongbiao Wang; Zhen Rong; Chunmei Mo
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.